Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: TH

Gene summary for TH

Gene summary.

Gene information	Species	Human
	Gene symbol	TH
	Gene ID	7054
	Gene name	tyrosine hydroxylase
	Gene Alias	DYT14
	Cytomap	11p15.5
	Gene Type	protein-coding
	GO ID	GO:0000003
	UniProtAcc	P07101

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
7054	TH	C04	Human	Oral cavity	OSCC	2.26e-15	7.94e-01	0.2633
7054	TH	C21	Human	Oral cavity	OSCC	3.65e-07	1.94e-01	0.2678
7054	TH	C30	Human	Oral cavity	OSCC	2.87e-17	6.63e-01	0.3055
7054	TH	C51	Human	Oral cavity	OSCC	4.98e-04	2.56e-01	0.2674
7054	TH	SYSMH5	Human	Oral cavity	OSCC	3.73e-03	1.34e-01	0.0647
7054	TH	P4_cSCC	Human	Skin	cSCC	3.76e-02	9.18e-02	-0.00290000000000005

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:003249617	Oral cavity	OSCC	response to lipopolysaccharide	178/7305	343/18723	7.27e-07	1.03e-05	178
GO:000911719	Oral cavity	OSCC	nucleotide metabolic process	243/7305	489/18723	7.80e-07	1.09e-05	243
GO:00611579	Oral cavity	OSCC	mRNA destabilization	55/7305	84/18723	8.05e-07	1.12e-05	55
GO:00434054	Oral cavity	OSCC	regulation of MAP kinase activity	101/7305	177/18723	8.13e-07	1.12e-05	101
GO:00507799	Oral cavity	OSCC	RNA destabilization	57/7305	88/18723	8.70e-07	1.19e-05	57
GO:004851116	Oral cavity	OSCC	rhythmic process	157/7305	298/18723	1.00e-06	1.36e-05	157
GO:004586120	Oral cavity	OSCC	negative regulation of proteolysis	181/7305	351/18723	1.01e-06	1.37e-05	181
GO:00109483	Oral cavity	OSCC	negative regulation of cell cycle process	155/7305	294/18723	1.11e-06	1.48e-05	155
GO:000038016	Oral cavity	OSCC	alternative mRNA splicing, via spliceosome	51/7305	77/18723	1.19e-06	1.59e-05	51
GO:003312018	Oral cavity	OSCC	positive regulation of RNA splicing	29/7305	37/18723	1.21e-06	1.61e-05	29
GO:00063991	Oral cavity	OSCC	tRNA metabolic process	101/7305	179/18723	1.65e-06	2.15e-05	101
GO:00019594	Oral cavity	OSCC	regulation of cytokine-mediated signaling pathway	87/7305	150/18723	1.82e-06	2.35e-05	87
GO:004343419	Oral cavity	OSCC	response to peptide hormone	208/7305	414/18723	1.83e-06	2.35e-05	208
GO:00094511	Oral cavity	OSCC	RNA modification	95/7305	167/18723	2.05e-06	2.62e-05	95
GO:005507610	Oral cavity	OSCC	transition metal ion homeostasis	81/7305	138/18723	2.13e-06	2.72e-05	81
GO:000862516	Oral cavity	OSCC	extrinsic apoptotic signaling pathway via death domain receptors	53/7305	82/18723	2.30e-06	2.92e-05	53
GO:00467779	Oral cavity	OSCC	protein autophosphorylation	123/7305	227/18723	2.31e-06	2.93e-05	123
GO:20007563	Oral cavity	OSCC	regulation of peptidyl-lysine acetylation	43/7305	63/18723	2.43e-06	3.06e-05	43
GO:00603384	Oral cavity	OSCC	regulation of type I interferon-mediated signaling pathway	28/7305	36/18723	2.45e-06	3.08e-05	28
GO:190331220	Oral cavity	OSCC	negative regulation of mRNA metabolic process	58/7305	92/18723	2.59e-06	3.23e-05	58

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0501230	Oral cavity	OSCC	Parkinson disease	188/3704	266/8465	1.82e-19	1.52e-17	7.75e-18	188
hsa05012113	Oral cavity	OSCC	Parkinson disease	188/3704	266/8465	1.82e-19	1.52e-17	7.75e-18	188

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SNV

Missense_Mutation

c.58N>C

p.Glu20Gln

p.E20Q

P07101

protein_coding

deleterious_low_confidence(0.01)

probably_damaging(0.998)

TCGA-E2-A1LS-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Cyclophosphamide

SNV

Missense_Mutation

novel

c.307N>A

p.Ala103Thr

p.A103T

P07101

protein_coding

tolerated(0.31)

benign(0.055)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

SNV

Missense_Mutation

rs760640869

c.374N>T

p.Ser125Leu

p.S125L

P07101

protein_coding

deleterious(0.01)

benign(0.058)

TCGA-EA-A3QD-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Chemotherapy

cisplatin

SNV

Missense_Mutation

c.235N>A

p.Glu79Lys

p.E79K

P07101

protein_coding

deleterious(0.04)

probably_damaging(0.957)

TCGA-MY-A5BD-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

SNV

Missense_Mutation

rs372409517

c.677N>T

p.Ser226Leu

p.S226L

P07101

protein_coding

deleterious(0.01)

possibly_damaging(0.661)

TCGA-A6-6780-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

SNV

Missense_Mutation

novel

c.1201N>C

p.Tyr401His

p.Y401H

P07101

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AA-3663-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Unknown

SNV

Missense_Mutation

novel

c.944N>A

p.Gly315Asp

p.G315D

P07101

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AA-A010-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Chemotherapy

folinic

SNV

Missense_Mutation

rs757607038

c.806C>T

p.Thr269Met

p.T269M

P07101

protein_coding

deleterious(0.04)

possibly_damaging(0.904)

TCGA-AA-A022-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

SNV

Missense_Mutation

c.721N>A

p.Ala241Thr

p.A241T

P07101

protein_coding

deleterious(0)

probably_damaging(0.992)

TCGA-F4-6703-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Unknown

SNV

Missense_Mutation

rs200751977

c.1492G>A

p.Asp498Asn

p.D498N

P07101

protein_coding

deleterious(0.02)

benign(0.077)

TCGA-EI-6917-01

Colorectum

rectum adenocarcinoma

Male

<65

III/IV

Chemotherapy

5fluorouracil+oxaciplatina+l-folinian

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
7054	TH	ENZYME, DRUGGABLE GENOME		L-Phenylalanine	PHENYLALANINE
7054	TH	ENZYME, DRUGGABLE GENOME		methylphenidate	METHYLPHENIDATE	26810137
7054	TH	ENZYME, DRUGGABLE GENOME		metyrosine	METYROSINE
7054	TH	ENZYME, DRUGGABLE GENOME		EPO	EPOETIN ALFA	16368081
7054	TH	ENZYME, DRUGGABLE GENOME		TETRAHYDROBIOPTERIN	SAPROPTERIN
7054	TH	ENZYME, DRUGGABLE GENOME		SERTRALINE HYDROCHLORIDE		8629887
7054	TH	ENZYME, DRUGGABLE GENOME		DEHYDROEPIANDROSTERONE	PRASTERONE	8704732
7054	TH	ENZYME, DRUGGABLE GENOME	inhibitor	CHEMBL1200862	METYROSINE
7054	TH	ENZYME, DRUGGABLE GENOME		IFN		8724983
7054	TH	ENZYME, DRUGGABLE GENOME		DOXYCYCLINE	DOXYCYCLINE	15585109

Page: 1 2 3 4